Cardiomyopathy (Hypertrophic)

Management of HCM.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
Cardiology

Clinical Guidelines

2023 ESC Guidelines for the management of cardiomyopathies
National
NICE guideline [NG180]
National
NICE Technology Appraisal Guidance [TA913]: Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy
National
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Local
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Local
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Local
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Local
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Local
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Local
2020 AHA/ACC Hypertrophic Cardiomyopathy Guideline
Local
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Hypertrophic Cardiomyopathy
Local
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Patients With Hypertrophic Cardiomyopathy
Local
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Patients With Hypertrophic Cardiomyopathy
Local